Tema Etfs LLC Purchases Shares of 9,580 Masimo Co. (NASDAQ:MASI)

Tema Etfs LLC acquired a new stake in Masimo Co. (NASDAQ:MASI - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 9,580 shares of the medical equipment provider's stock, valued at approximately $1,584,000.

A number of other institutional investors also recently made changes to their positions in the business. Envestnet Asset Management Inc. raised its holdings in Masimo by 17.3% during the 4th quarter. Envestnet Asset Management Inc. now owns 31,107 shares of the medical equipment provider's stock valued at $5,142,000 after buying an additional 4,579 shares during the last quarter. Lecap Asset Management Ltd. bought a new stake in Masimo during the 4th quarter valued at $1,607,000. Nisa Investment Advisors LLC raised its holdings in Masimo by 16,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,052 shares of the medical equipment provider's stock valued at $835,000 after buying an additional 5,022 shares during the last quarter. Trust Point Inc. bought a new stake in Masimo during the 4th quarter valued at $230,000. Finally, Barclays PLC raised its holdings in Masimo by 152.6% during the 3rd quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock valued at $5,329,000 after buying an additional 24,137 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

Insider Activity at Masimo

In other news, COO Bilal Muhsin sold 10,000 shares of the stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $163.28, for a total value of $1,632,800.00. Following the transaction, the chief operating officer now owns 24,172 shares in the company, valued at $3,946,804.16. This represents a 29.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the transaction, the director now owns 16,581 shares in the company, valued at $2,754,601.53. This trade represents a 11.02% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,053 shares of company stock valued at $6,998,565. 9.70% of the stock is owned by insiders.

Masimo Stock Up 0.7%

Shares of Masimo stock traded up $1.04 during trading on Tuesday, hitting $156.17. The company's stock had a trading volume of 524,522 shares, compared to its average volume of 651,630. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The company has a fifty day simple moving average of $159.81 and a two-hundred day simple moving average of $167.57. The company has a market capitalization of $8.47 billion, a PE ratio of 107.70 and a beta of 1.23. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The medical equipment provider reported $1.36 EPS for the quarter, beating the consensus estimate of $1.24 by $0.12. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $372.00 million for the quarter, compared to the consensus estimate of $367.79 million. During the same period in the prior year, the firm posted $0.77 EPS. Masimo's revenue for the quarter was down 24.5% on a year-over-year basis. Equities research analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on MASI. Wells Fargo & Company lowered their price target on shares of Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a report on Wednesday, May 7th. Raymond James decreased their price objective on shares of Masimo from $204.00 to $185.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. BTIG Research set a $193.00 price objective on shares of Masimo and gave the stock a "buy" rating in a report on Wednesday, May 7th. Piper Sandler restated an "overweight" rating and issued a $200.00 price objective (down from $215.00) on shares of Masimo in a report on Wednesday, May 7th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Masimo has a consensus rating of "Moderate Buy" and an average price target of $191.60.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.